Asymptomatic infection or mild symptoms of COVID-19 confirmed by real-time polymerase chain reaction (RT-PCR) SARS-CoV-2, COVID-19, povidone iodine, upper respiratory tract
Conditions
Interventions
If patient is willing to participate in the study, this following intervention will be performed in all patients
1. Specimen collection by nasal swab at left nose (control specimen)
2. Administration of 0.4% PVI solution at left and right noses
3. Wait 3 minutes and specimen collection by nasal swab at left and
Experimental Drug
Sponsors
Health System Research Institute (HSRI)
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-60 years, 2. Asymptomatic or mild symptom of COVID-19 by RT-PCR, 3. Willing to participate in the present study, 4. Cycle threshold of RT-PCR for SARS-CoV-2 less than 25 (within 3 days before enrollment)
Exclusion criteria
Exclusion criteria: 1. Severe allergy to seafood or iodine, 2. Pregnancy or lactation, 3. Thyroid gland enlargement or thyrotoxicosis, 4. Receiving favipiravir or remdesivir treatment before enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Viral culture 3 minutes after administration Growth | — |
Secondary
| Measure | Time frame |
|---|---|
| Viral culture 4 hours after administration Growth,RT-PCR 3 minutes after administration Cycle threshold,RT-PCR 4 hours after administration Cycle threshold,Adverse event During and 4 hours after administration Presence | — |
Countries
Thailand
Contacts
Public ContactRUJIPAS SIRIJATUPHAT
Faculty of Medicine Siriraj Hospital
Outcome results
None listed